Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AABA
Altaba Inc
AABA
|
+$784M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$504M |
| 3 |
General Dynamics
GD
|
+$348M |
| 4 |
XL
XL Group Ltd.
XL
|
+$329M |
| 5 |
Keurig Dr Pepper
KDP
|
+$194M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$618M |
| 2 |
MON
Monsanto Co
MON
|
+$543M |
| 3 |
COL
Rockwell Collins
COL
|
+$151M |
| 4 |
ABLX
Ablynx NV
ABLX
|
+$134M |
| 5 |
PPLI
People Inc
PPLI
|
+$112M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.57% |
| 2 | Technology | 19.02% |
| 3 | Financials | 14.39% |
| 4 | Communication Services | 11.79% |
| 5 | Industrials | 10.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Arcus Biosciences
RCUS
$3.86B
| – | – |
-11,422
| Closed | -$176K |
|
102
Tronox
TROX
$888M
| – | – |
-688,006
| Closed | -$12.7M |
|
103
VICI Properties
VICI
$29.2B
| – | – |
-337,049
| Closed | -$6.07M |
|
104
Xencor
XNCR
$2.07B
| – | – |
-149,900
| Closed | -$4.49M |
|
105
XPO
XPO
$23.2B
| – | – |
-1,373,412
| Closed | -$48.4M |
|
|
CBAY
106
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-550,000
| Closed | -$7.14M |
|
|
BOLD
107
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-320,000
| Closed | -$9.62M |
|
|
AHL
108
DELISTED
ASPEN Insurance Holding Limited
AHL
| – | – |
-194,341
| Closed | -$8.72M |
|
|
TWX
109
DELISTED
Time Warner Inc
TWX
| – | – |
-1,020,000
| Closed | -$96.5M |
|
|
ABLX
110
DELISTED
Ablynx NV
ABLX
| – | – |
-2,450,000
| Closed | -$134M |
|
|
MON
111
CALL
DELISTED
Monsanto Co
MON
| – | – |
-2,000,000
| Closed | -$233M |
|
|
MON
112
DELISTED
Monsanto Co
MON
| – | – |
-4,650,000
| Closed | -$543M |
|
|
AVXS
113
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-294,000
| Closed | -$36.3M |
|
|
CBI
114
DELISTED
Chicago Bridge & Iron Nv
CBI
| – | – |
-660,000
| Closed | -$9.5M |
|
Similar funds
Thomas Steyer's Q2 2018 Portfolio in Review
As of Q2 2018, Thomas Steyer held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Thomas Steyer deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.
- Thomas Steyer's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
- Thomas Steyer added most to Altaba Inc in Q2 2018, an estimated $784M increase.
- Thomas Steyer's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
- Thomas Steyer fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
- Thomas Steyer's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
- Thomas Steyer opened 28 new positions and closed 20 in Q2 2018.
- Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $16.2B.
Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.